Impact of class of immunosuppression on vaccine response in the IMID group
| csDMARDS | bDMARDS | tsDMARDS | Controls | |
| Continue group | ||||
| Detectable SARS-CoV2 IgG antibodies* | ||||
| 6 months postvaccination (p=0.311) | 21/22 (95.5) | 26/27 (96.3) | 22/26 (84.6) | 37/42 (88.1) |
| p=0.320 | p=0.392 | p=0.723 | ||
| Postbooster vaccine dose | 28/28 (100) | 25/25 (100) | 25/25 (100) | 36/36 (100) |
| Median SARS-CoV2 IgG Ab titre† | ||||
| 6 months postvaccination (p=0.030) | 5.8 (2.3–13.0) | 2.6 (1.4–9.4) | 2.1 (1.0–4.1) | 5.7 (1.8–10.6) |
| 5.3 (3.2–9.0) | 3.7 (2.3–5.8) | 2.2 (1.4–3.6) | 4.8 (3.2–7.3) | |
| p=0.798 | p=0.357 | p=0.010 | ||
| Post booster vaccine dose (p=0.188) | 129.5 (73.4–289.4) | 93.2 (55.7–241.8) | 74.7 (36.7–156.5) | 199.9 (64.9–347.9) |
| 123.5 (77.2–197.6) | 108.8 (65.6–180.5) | 74.8 45.5–123.0) | 139.6 (92.8–210.1) | |
| p=0.752 | p=0.378 | p=0.068 | ||
| Withhold group | ||||
| Detectable SARS-CoV2 IgG antibodies* | ||||
| 6 months postvaccination (p=0.476) | 13/13 (100) | 18/21 (85.7) | 22/25 (88.0) | 37/42 (88.1) |
| p=0.324 | p=1.00 | p=1.00 | ||
| Postbooster vaccine dose | 15/15 (100) | 19/19 (100) | 24/24 (100) | 36/36 (100) |
| Median SARS-CoV2 IgG Ab titre† | ||||
| 6 months postvaccination (p=0.609) | 10.1 (6.5–12.9) | 7.7 (1.5–19.0) | 3.9 (2.2–14.7) | 5.7 (1.8–10.6) |
| 9.7 (4.7–20.1) | 6.6 (3.3–13.1) | 5.4 (3.1–9.6) | 4.8 (3.2–7.3) | |
| p=0.091 | p=0.337 | p=0.600 | ||
| Postbooster vaccine dose (p=0.085) | 196.8 (88.5–426.4) | 96.1 (55.0–145.6) | 97.8 (72.5–197.3) | 199.9 (64.9–347.9) |
| 190.7 (119.7–303.8) | 82.4 (52.3–129.8) | 89.7 (51.4–156.7) | 139.6 (92.8–210.1) | |
| p=0.406 | p=0.110 | p=0.240 |
Data are presented as proportions (%) or median (IQR).
Geometric means and corresponding 95% CI are shown in blue.
Comparison of DMARD categories with healthy controls using Fisher’s exact test or Wilcoxon-Mann-Whitney test as appropriate with significance cut-off 5%.
*Using Fisher’s exact test with significance cut-off 5%.
†Using Kruskal-Wallis test among the immunosuppression groups only with significance cut-off 5%.
IMID, immune-mediated inflammatory diseases.